Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma

Li Zhang, Hui Du, Tai-wu Xiao, Ji-zhu Liu, Guo-zhen Liu, Jing-xia Wang, Guangyao Li, Lexin Wang

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Objective: To investigate the expression of PD-1 and TIM-3 in CD3+ T cells in patients with diffuse large B-cell lymphoma (DLBCL). Methods: A retrospective analysis was conducted on data from 46 patients with newly diagnosed DLBCL and 30 healthy people. Flow cytometry was used to detect the expression of PD-1 and TIM-3 before and after chemotherapy. Results: Compared to healthy control, the expression of PD-1 and TIM-3 in patients with DLBCL was increased in CD3+ T cells. There is no significant change of PD-1 and TIM-3 in patients with stage I/II DLBCL, however, they were markedly increased in patients with stage III/IV DLBCL. The expression of PD-1 and TIM-3 elevated in DLBCL patients with B symptoms, IPI score >2 points and high level of LDH and Ki-67. After four courses of standard chemotherapy, PD-1 and TIM-3 expression level decreased. The treatment efficiency is higher in patients with low expression of PD-1 and TIM-3 than in patients with high PD-1 and TIM-3 expression. Conclusion: DLBCL patients have high expression level of PD-1 and TIM-3, which are related to DLBCL staging. PD-1 and TIM-3 expression levels are also related to the efficiency of chemotherapy. PD-1 and TIM-3 expression levels may be used as an indicator of chemotherapeutic efficacy in patients with DLBCL.
Original languageEnglish
Pages (from-to)83-87
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume75
DOIs
Publication statusPublished - Oct 2015

Fingerprint Dive into the research topics of 'Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this